|
EMA Q&A Rev. 22 (EMA/409815/2020 Rev.22)
|
|
5
|
3298
|
October 10, 2025
|
|
🇺🇸 US FDA- Generic Drug Science and Research Priority Initiatives for Fiscal Year (FY) 2026
|
|
0
|
306
|
October 6, 2025
|
|
Quantitative genotoxicity assessment of N-nitrosodimethylamine in mice by error-corrected next-generation sequencing and DNA methylation quantification for toxicity threshold determination
|
|
2
|
279
|
September 24, 2025
|
|
Computational Mechanistic Study on N-Nitrosation Reaction of Secondary Amines
|
|
0
|
387
|
August 25, 2025
|
|
Nitrite testing in Excipients
|
|
2
|
738
|
August 17, 2025
|
|
:canada: Health Canada Extended Deadline
|
|
5
|
883
|
August 3, 2025
|
|
Nitrosamine impurities in human medicines/ European Medicines Regulatory Network
|
|
0
|
376
|
July 29, 2025
|
|
Nitrosamine Control Strategies: From Risk Identification to Implementation
|
|
3
|
498
|
July 24, 2025
|
|
N-nitrosamine risk assessment in pharmaceuticals: Where are we from a regulatory point of view in 2025?
|
|
0
|
443
|
July 24, 2025
|
|
Highlights from the 13th meeting of the Nitrosamine Implementation Oversight Group (NIOG)
|
|
7
|
667
|
July 22, 2025
|
|
Analytical Procedures and Validation_Specificity parameter requirment
|
|
9
|
884
|
July 9, 2025
|
|
Addendum to ICH M7 on Risk Assessment and Control of N-Nitrosamine Impurities
|
|
8
|
3001
|
July 3, 2025
|
|
🚨 FDA deadline update
|
|
12
|
1508
|
June 30, 2025
|
|
Cleaning procedure for glassware used in the analysis of nitrosamines for LC-MS/MS
|
|
2
|
500
|
May 23, 2025
|
|
Nitrosamine Mitigation: A Path to Regulatory Compliance
|
|
1
|
536
|
May 11, 2025
|
|
Nitrosourea, aromatic n-nitroso copmounds
|
|
2
|
298
|
May 2, 2025
|
|
Autonomous CPCA Web-based calculator FREE
|
|
33
|
7645
|
April 30, 2025
|
|
Annex 2 WHO good practice considerations for the prevention and control of nitrosamines in pharmaceutical products
|
|
0
|
516
|
April 16, 2025
|
|
Nitrosamines Safety Operational Expert Group
|
|
0
|
180
|
April 16, 2025
|
|
Clobam Nitrosamine Impurity
|
|
0
|
259
|
April 8, 2025
|
|
Acceptance criteria for Nitrosamines Method Validation
|
|
3
|
600
|
March 14, 2025
|
|
CDER Drug Safety Priorities Fiscal Year 2023
|
|
2
|
742
|
February 27, 2025
|
|
Adjustment of the MDD with CYP inducers?
|
|
2
|
200
|
February 13, 2025
|
|
EMA nitrosamine Q&A Appendix 1 rev.7 published on Dec 13, 2024
|
|
8
|
3086
|
January 27, 2025
|
|
ICH M7 & Nitrosamines Impurities -Updates
|
|
15
|
5756
|
January 20, 2025
|
|
Control Strategy - Testing Frequency
|
|
10
|
742
|
January 20, 2025
|
|
🇲🇽 Mexico Q&A Live session streaming
|
|
7
|
849
|
January 6, 2025
|
|
Critical comparison of BMD and TD50 methods for the calculation of acceptable intakes for N-nitroso compounds -Pub
|
|
0
|
346
|
January 3, 2025
|
|
CHPA's response to the Control of Nitrosamine Impurities in Human Drugs rev.2
|
|
1
|
473
|
January 2, 2025
|
|
AI for pharmaceutical legislation, including nitrosamines
|
|
4
|
576
|
December 30, 2024
|